LinkedIn Icon
September 2018
Boston

2017 Speakers

Expand/Collapse

Mike Giffin
Scientist
Amgen

Andrea Hooper
Senior Principal Scientist, Targeted Therapeutics Discovery
Pfizer

Andrew Tsourkas
Professor, Bioengineering
University of Pennsylvania

Day One

Wednesday September 27 2017

15.45 | Site-Specific Bioconjugation Approaches for the Preparation of Novel Bispecific Antibody Platforms

Arnout Gerritsen
Associate Director, Assay & Bio-Analytical Science
Genmab

Christoph Spiess
Senior Scientist, Antibody Engineering
Genentech

Day One

Wednesday September 27 2017

15.15 | Engineered Fab Domains Promote Efficient Production of Bispecific Antibodies in a Single Cell

Christopher Murriel
Senior Scientist
OncoMed

Dale Ludwig
CSO, Biologics Technology, Oncology Research
Eli Lilly

Day One

Wednesday September 27 2017

13.30 | Avoiding Pitfalls in Format Design – Understanding Why Bispecifics Have Behaved Unexpectedly in the Past to Give a Greater Certainty in Moving into the Clinic in the Future

Feng Dong
Senior Scientist
Abbvie

Pre-conference Workshop B

Tuesday September 26

11.30 | Investigating Computational Approaches to Model Bispecific Therapeutics

Helene Finney
Director, Functional Screening
UCB

Hirotake Shiraiwa
Group Manager, Research Division
Chugai Pharmaceuticals

Janine Schuurman
Vice President, Research
Genmab

Day One

Wednesday September 27 2017

16.45 | Chair’s Closing Remarks

08.20 | Chair’s Opening Remarks

Jeff Way
Senior Staff Scientist, Wyss Institute
Harvard University

John Burke
Co-founder, President & CEO
Applied BioMath

Day One

Wednesday September 27 2017

09.30 | Model Aided Drug Invention Case Studies in Research: In silico Differentiation for Dual Targeting PD-1 and TIM-3 in I/O, and Predicting Optimal Drug Properties of a Bispecific Biologic to Maximize Tissue Targeting in OA

Jonathan Davis
Protein Design & Principal Scientist
Innovative Protein Engineer & Drug Designer, Bristol-Myers Squibb

Day Two

Thursday September 28 2017

15.30 | Chair’s Closing Remarks

08.50 | Chair’s Opening Remarks

Jonathan Lai
Associate Professor
Albert Einstein College of Medicine

Day Two

Thursday September 28 2017

14.30 | Bispecific Antibodies as Cross-Protective Filovirus Immunotherapeutics

Laurence Fayadat-Dilman
Director, Protein Sciences
Merck

Day One

Wednesday September 27 2017

16.15 | Developability & Analytical Characterization to Enable the Optimal Selection of Bispecific Antibodies

Marlon Hinner
Group Leader, In Vitro Display
Roche

Day One

Wednesday September 27 2017

14.15 | Panel Discussion: Investigating Comparisons Between Formats – Lessons Learned that will Inform Future Format Design

14.00 | Making Room for Two Paratopes on an Fv: Introducing the DutaFab Platform

Nai-Kong Cheung
Head, Neuroblastoma Program
MSKCC

Day One

Wednesday September 27 2017

09.00 | Engineering Bispecific Antibodies for Cancer therapy – a Unique Perspective for Pediatric Solid Tumors Spanning Three Decades

Nina Weisser
Principal Scientist, Oncology
Zymeworks

Day Two

Thursday September 28 2017

09.30 | Preclinical and Clinical Development of a Novel Biparatopic HER2 Antibody in Low to High HER2-Expressing Cancers

Paul Moore
Vice President, Cell Biology & Immunology
MacroGenics

Day Two

Thursday September 28 2017

09.00 | Clinical Development of Bispecific DART® Molecules – Experiences to Date

Prasad Adusumilli
Deputy Chief, Thoracic Service
MSKCC

Robert Mabry
Senior Director, Protein Sciences & Antibody Technology
Jounce

Day One

Wednesday September 27 2017

14.15 | Panel Discussion: Investigating Comparisons Between Formats – Lessons Learned that will Inform Future Format Design

Shawn Foley
Attorney, Intellectual Property
Burns & Levinson

Pre-conference Workshop C

Tuesday September 26

15.00 | IP and Licensing: Navigating the Landscape

Stan Blein
Senior Director & Head, Antibody Engineering Innovation & Development
Glenmark

Day One

Wednesday September 27 2017

14.15 | Panel Discussion: Investigating Comparisons Between Formats – Lessons Learned that will Inform Future Format Design

Syd Johnson
Vice President, Antibody Engineering
MacroGenics

Tariq Ghayur
Senior Research Fellow
Abbvie

Day One

Wednesday September 27 2017

08.30 | Lessons Learned from the Clinical Development of Bispecifics

Tina Furebring
Vice President, Research & Development
Alligator Bioscience

Pre-conference Workshop A

Tuesday September 26

08.00 | Investigating Synergistic Checkpoint Modulator Targeting – How Can We Select Rational Combinations?

Yoshiko Akamatsu
Senior Principal Research Scientist
Abbvie

Yunxiang Zhu
Senior Director
Genzyme

Day Two

Thursday September 28 2017

15.00 | Novel Bispecific Antibody as a Potential Treatment for Alpha-Dystroglycanopathy